Jolanta Kunikowska1, Radosław Kuliński1, Kristoff Muylle2, Henryk Koziara3, Leszek Królicki1. 1. From the Nuclear Medicine Department, Medical University of Warsaw, Poland. 2. Department of Nuclear Medicine, University Hospital Brussels/UZ Brussel (VUB), Brussels, Belgium. 3. Department of Neurosurgery, The Maria Skłodowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland.
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most common and most aggressive primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of recurrences occur at the surgical margins. Currently, limited data are available in the literature on the possible use of Ga-prostate-specific membrane antigen (PSMA-11) for diagnosis of recurrence in GBM patients. The aim was to assess the feasibility and potential of Ga-PSMA-11 PET/CT as a diagnostic procedure in patients with histologically confirmed of GBM and suspected recurrent disease on MRI. RESULTS: No radiopharmaceutical-related adverse events were noted. Characterization of recurrent disease with MRI included T2-weighted fast spin-echo images, fluid-attenuated inversion recovery and diffusion-weighted imaging sequences, and gadolinium enhanced T1-weighted images. Visual interpretation of PET showed increased accumulation of Ga-PSMA-11 in recurrent lesion detected by T1 contrast enhanced and diffusion-weighted imaging images in all patients with a median SUVmax of the tumor of 6.5 and an SUVmean of 3.5. The median tumor-to-background brain ratio and tumor-to-liver ratio obtained from Ga-PSMA-11 PET/CT were 96.7 and 0.8, respectively. CONCLUSIONS: The extremely low background uptake in normal brain tissue and consequently high tumor-to-brain ratio make Ga-PSMA-11 PET/CT highly promising for diagnosis of recurrent disease in GBM patients. Although PSMA expression in recurrent GBM also opens a potential way for targeted peptide therapy with α/β-emitters as well as for prediction of treatment with antiangiogenic agents, the low tumor-to-liver ratio observed in the majority of patients in this study suggests a limited role of radiolabeled PSMA ligands for targeted radionuclide therapy of recurrent GBM.
BACKGROUND:Glioblastoma multiforme (GBM) is the most common and most aggressive primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of recurrences occur at the surgical margins. Currently, limited data are available in the literature on the possible use of Ga-prostate-specific membrane antigen (PSMA-11) for diagnosis of recurrence in GBMpatients. The aim was to assess the feasibility and potential of Ga-PSMA-11 PET/CT as a diagnostic procedure in patients with histologically confirmed of GBM and suspected recurrent disease on MRI. RESULTS: No radiopharmaceutical-related adverse events were noted. Characterization of recurrent disease with MRI included T2-weighted fast spin-echo images, fluid-attenuated inversion recovery and diffusion-weighted imaging sequences, and gadolinium enhanced T1-weighted images. Visual interpretation of PET showed increased accumulation of Ga-PSMA-11 in recurrent lesion detected by T1 contrast enhanced and diffusion-weighted imaging images in all patients with a median SUVmax of the tumor of 6.5 and an SUVmean of 3.5. The median tumor-to-background brain ratio and tumor-to-liver ratio obtained from Ga-PSMA-11 PET/CT were 96.7 and 0.8, respectively. CONCLUSIONS: The extremely low background uptake in normal brain tissue and consequently high tumor-to-brain ratio make Ga-PSMA-11 PET/CT highly promising for diagnosis of recurrent disease in GBMpatients. Although PSMA expression in recurrent GBM also opens a potential way for targeted peptide therapy with α/β-emitters as well as for prediction of treatment with antiangiogenic agents, the low tumor-to-liver ratio observed in the majority of patients in this study suggests a limited role of radiolabeled PSMA ligands for targeted radionuclide therapy of recurrent GBM.
Authors: Maximilian A Kirchner; Adrien Holzgreve; Matthias Brendel; Michael Orth; Viktoria C Ruf; Katja Steiger; Dennis Pötter; Lukas Gold; Marcus Unterrainer; Lena M Mittlmeier; Enio Barci; Roland E Kälin; Rainer Glass; Simon Lindner; Lena Kaiser; Jessica Maas; Louisa von Baumgarten; Harun Ilhan; Claus Belka; Johannes Notni; Peter Bartenstein; Kirsten Lauber; Nathalie L Albert Journal: Front Oncol Date: 2021-11-17 Impact factor: 6.244
Authors: Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser Journal: Mol Imaging Date: 2022-04-15 Impact factor: 3.250
Authors: Peter Truckenmueller; Josefine Graef; Michael Scheel; Peter Vajkoczy; David Capper; David Kaul; Christian Furth; Holger Amthauer; Winfried Brenner; Julia Sophie Onken Journal: Front Oncol Date: 2022-09-02 Impact factor: 5.738
Authors: Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923
Authors: M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-12 Impact factor: 9.236